These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34729217)

  • 41. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.
    Crawford ED; Petrylak DP; Higano CS; Kibel AS; Kantoff PW; Small EJ; Shore ND; Ferrari A
    Can J Urol; 2015 Dec; 22(6):8048-55. PubMed ID: 26688132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.
    Handy CE; Antonarakis ES
    Future Oncol; 2018 Apr; 14(10):907-917. PubMed ID: 29260582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists.
    Garcia JA
    Ther Adv Med Oncol; 2011 Mar; 3(2):101-8. PubMed ID: 21789160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current status of immunological approaches for the treatment of prostate cancer.
    Drake CG; Antonarakis ES
    Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A New Era of Immunotherapy in Prostate Cancer.
    Pizzola C; Rizvi SM; Joshi M
    Curr Mol Pharmacol; 2016; 9(3):217-225. PubMed ID: 26177645
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment.
    Fujio K; Watanabe M; Ueki H; Li SA; Kinoshita R; Ochiai K; Futami J; Watanabe T; Nasu Y; Kumon H
    Oncol Rep; 2015 Apr; 33(4):1585-92. PubMed ID: 25632844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.
    Schellhammer PF; Chodak G; Whitmore JB; Sims R; Frohlich MW; Kantoff PW
    Urology; 2013 Jun; 81(6):1297-302. PubMed ID: 23582482
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
    Gulley JL; Madan RA; Heery CR
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.
    Mandl SJ; Rountree RB; Dela Cruz TB; Foy SP; Cote JJ; Gordon EJ; Trent E; Delcayre A; Franzusoff A
    J Immunother Cancer; 2014; 2(1):34. PubMed ID: 25328681
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
    Mulders PF; De Santis M; Powles T; Fizazi K
    Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
    Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
    J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sipuleucel-T: immunotherapy for advanced prostate cancer.
    Olson BM; McNeel DG
    Open Access J Urol; 2011 May; 3():49-60. PubMed ID: 24198636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
    Autio KA; Higano CS; Nordquist L; Appleman LJ; Zhang T; Zhu XH; Babiker H; Vogelzang NJ; Prasad SM; Schweizer MT; Madan RA; Billotte S; Cavazos N; Bogg O; Li R; Chan K; Cho H; Kaneda M; Wang IM; Zheng J; Tang SY; Hollingsworth R; Kern KA; Petrylak DP
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36948505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity.
    Karan D; Van Veldhuizen P
    Immunotherapy; 2012 Jun; 4(6):577-80. PubMed ID: 22788125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.
    Graff JN; Drake CG; Beer TM
    Urology; 2013 Feb; 81(2):381-3. PubMed ID: 23374810
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.
    McNeel DG; Gardner TA; Higano CS; Kantoff PW; Small EJ; Wener MH; Sims RB; DeVries T; Sheikh NA; Dreicer R
    Cancer Immunol Res; 2014 Oct; 2(10):988-99. PubMed ID: 25189164
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic vaccines for prostate cancer.
    Cha E; Fong L
    Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
    Kantoff PW; Schuetz TJ; Blumenstein BA; Glode LM; Bilhartz DL; Wyand M; Manson K; Panicali DL; Laus R; Schlom J; Dahut WL; Arlen PM; Gulley JL; Godfrey WR
    J Clin Oncol; 2010 Mar; 28(7):1099-105. PubMed ID: 20100959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Gamat-Huber M; Jeon D; Johnson LE; Moseman JE; Muralidhar A; Potluri HK; Rastogi I; Wargowski E; Zahm CD; McNeel DG
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33008010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.